P. Billiald, Museum national d’Histoire naturelle, CNRS FRE 3206, CP39, 12, rue Buffon, 75231 Paris cedex 05, France Fax: +33 140 793 594 Tel: +33 140 793 155 E-mail: firstname.lastname@example.org M. Jandrot-Perrus, Inserm U698, Hôpital Bichat, 46 rue Henri Huchard; University Paris 7, Paris, France Fax: +33 140 258 602 Tel: +33 140 256 531 E-mail: email@example.com
Platelet adhesion and aggregation at the site of vascular injury is essential for hemostasis, but can also lead to arterial occlusion in thrombotic disorders. Glycoprotein (GP) VI is the major platelet membrane receptor that interacts directly with collagen, the most thrombogenic compound in the blood vessels. GPVI could therefore be a major therapeutic target. Fab fragments of the anti-GPVI murine monoclonal IgG 9O12 have previously been shown to completely block collagen-induced platelet aggregation, to inhibit the procoagulant activity of collagen-stimulated platelets, and to prevent thrombus formation under arterial flow conditions without significantly prolonging the bleeding time. Here, we engineered recombinant scFvs that preserve the functional properties of 9O12, and could constitute building blocks for designing new compounds with potentially therapeutic antithrombotic properties. First, the 9O12 variable domains were cloned, sequenced, and expressed as a recombinant murine scFv, which was fully characterized. This scFv preserved all the characteristics that make 9O12 Fab potentially useful for therapeutic applications, including its high affinity for GPVI, ability to inhibit platelet adhesion, and aggregation with collagen under arterial flow conditions. A humanized version of this scFv was also designed after complementarity-determining region grafting and structural refinements using homology-based modeling. The final product was produced in recombinant bacteria. It retained GPVI-binding specificity and high affinity, which are the main parameters usually impaired by humanization procedures. This is a simple, efficient and straightforward method that could also be used for humanizing other antibodies.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.
Platelets play a crucial role in thrombus formation and limiting blood loss from sites of vascular injury. This is a complex process and entails the following series of steps: adhesion of platelets to the damaged vascular subendothelium, activation of the platelets, their recruitment and, finally, aggregation. In some circumstances, such as disruption of the atherosclerotic plaques, platelet activation can lead to arterial occlusion and irreversible tissue damage. Acute coronary and cerebrovascular accidents usually result from this phenomenon, and they are currently the leading causes of death in the world. As a consequence, antiplatelet drugs constitute a major class of therapeutics intended to prevent and/or reverse platelet aggregation in arterial thrombosis . Drugs that act on the platelet recruitment step have been used for a long time, and include inhibitors of cyclooxygenase (aspirin), phosphodiesterase inhibitors (dipyridamole) and, more recently, ADP receptor antagonists (clopidogrel). A chimeric antibody fragment (Fab) (abciximab) directed to glycoprotein (GP) IIb-GPIIIa that acts on the final step of the aggregation has also been approved for specific subsets of patients with acute coronary disease. However, all of the drugs currently utilized to counteract platelet function suffer from a lack of potency and/or specificity, and major risks of hemorrhage and thrombocytopenia are associated with their use . There is therefore a continuing need for new and improved drugs that will inhibit platelet function in diseases characterized by thrombosis, and in particular for drugs with limited hemorrhagic effects, this point being crucial for safe antithrombotic therapy.
An attractive antithrombotic strategy would consist of targeting the initial interaction of platelets with the vessel wall rather than the later recruitment and aggregation phases. GPVI is the major receptor that interacts directly with collagen, which is the most thrombogenic compound in the vessel wall. GPVI mediates platelet aggregation and secretion of the secondary agonists responsible for thrombus growth. In addition, the release of growth factors and cytokines contributes to the recruitment of inflammatory cells and to the proliferation of smooth muscle cells, leading to stenosis [3,4]. Finally, GPVI expression is restricted to the platelet lineage . There is also direct experimental and clinical evidence that platelets deficient in GPVI cannot be activated by collagen, and that a deficiency in GPVI expression does not produce major bleeding [6,7]. For all of these reasons, GPVI antagonists can be expected to be good candidates for preventing secondary thrombosis in an efficient and specific manner and also to be associated with a low risk of hemorrhage.
GPVI antagonists can be designed in several ways. One approach consists of generating soluble GPVI recombinant proteins or GPVI mimetics that will compete with platelets to bind to collagen. Encouraging results have been reported in a murine thrombosis model using the extracellular domain of murine GPVI produced in fusion with the human immunoglobulin Fc domain . However, these results have not been confirmed, and the use of competitive ligands such as soluble recombinant GPVI may be associated with considerable pharmacological and functional drawbacks . A more effective way to block platelet GPVI–collagen interactions consists of directly targeting GPVI with molecules such as specific antibodies. Previous studies have shown that targeting murine GPVI with the rat monoclonal antibody JAQ1 abolishes collagen responses in circulating platelets, leading to the depletion of the receptor and to long-term antithrombotic protection in mice [10–12]. However, this antibody does not crossreact with human GPVI. Recombinant scFvs directed against human GPVI have also been reported over the last few years [13–15]. These antibody fragments have been isolated from combinatorial phage display libraries expressing human scFvs, and some of them specifically block GPVI binding to collagen under experimental conditions. However, they all exhibit low affinity for their target (KD in the range of 10−7m), making them unsuitable for therapeutic applications. Recently, monoclonal Fab fragments derived from four distinct murine hybridomas (OM 1–4) were found to inhibit the binding of GPVI to collagen, collagen-induced secretion and thromboxane A2 formation in vitro, as well as ex vivo collagen-induced platelet aggregation after intravenous injection in cynomolgus monkeys [16,17]. Fab OM 4 also inhibited thrombus formation in vivo in rats without prolonging the bleeding time, thus confirming the therapeutic potential of antibody fragments directed to GPVI . A human–mouse chimeric monoclonal antibody (cF1232) has also been reported to cause GPVI immunodepletion with a long-term in vivo antiplatelet effect in monkeys. However, such a process is not reversible and implies GPVI depletion on megakaryocytes, the consequence of which has not been addressed .
Another murine monoclonal antibody-derived Fab (9O12) specific for human GPVI has been developed and characterized by our group . This high-affinity inhibitory monovalent Fab not only completely blocks collagen-induced platelet aggregation, but also inhibits the procoagulant activity of collagen-stimulated platelets, and prevents thrombus formation under both static and flow conditions. However, the immunogenicity of murine antibody fragments is a major obstacle to their clinical development, so it is necessary to reduce this immunogenicity by a humanization procedure.
Here, we report the cloning and sequencing of 9O12 variable domains, and the engineering and detailed evaluation of the derived scFv produced in recombinant bacteria. In view of its high potential, the murine scFv (mscFv 9O12) was then humanized. At this stage, the 9O12 complementarity-determining regions (CDRs) were grafted onto closely related human antibody variable domains, and refinements were carried out after in silico modeling and inspection of the paratope. The cDNA encoding the humanized construct (hscFv 9O12) was chemically synthesized, cloned, and expressed in recombinant bacteria. We were able to purify this molecule and to test it on human platelets by flow cytometry analysis. The final product did not suffer loss of affinity and specificity, which are the parameters usually affected by humanization procedures.
Design, bacterial expression and purification of mscFv 9O12
cDNAs encoding the VH and VL domains of 9O12 were derived from hybridoma cell mRNA in an RT-PCR using consensus primers. Sequencing of the PCR product corresponding to the VH domain led to a single sequence, whereas the sequence of the PCR product corresponding to the VL domain was scrambled because of the amplification of the aberrant MOPC21-derived Vk gene. Digestion of the VL PCR product with BciVI, and treatment as previously reported, made it possible to bypass the aberrant MOPC21-derived transcript, and to clone the 9O12 kappa light chain V-gene . To ensure accuracy, VH and VL cDNAs were independently amplified from two distinct batches of mRNA. Sequencing confirmed that no mutation had occurred during the PCR reaction. The 9O12 VH and VL cDNA sequences are now registered in the EMBL data bank (AM 887763 and AM 887764, respectively).The scFv-encoding gene derived from the variable regions of 9O12 [VH and VL linked together via a short linker (G4S)3] was then constructed, and inserted in frame with the pelB signal sequence, upstream of the c-Myc tag, into the pSW1 expression vector (pSW–mscFv 9O12). The construct is shown in Fig. 1A. Plasmid pSW–mscFv 9O12 was cloned into the TOPPI Escherichia coli strain, and the recombinant protein was produced and purified by affinity chromatography using GPVI–Sepharose gel. This procedure made it possible to recover fully functional scFv with a yield of 200 μg·L−1 of culture. The preparation was homogeneous, as shown by SDS/PAGE under reducing conditions, western blot using the antibody against c-Myc, and MS analysis, which indicated an experimental relative molecular mass (M + H+) of 28 402.3 Da, close to the theoretical molecular mass of 28 394.5 Da calculated from the amino acid sequence (Fig. 1B). The purified scFv was further analyzed by size exclusion chromatography (Fig. 1C). This revealed the presence of a main peak (62%) eluting at 12.5 mL with an apparent molecular mass of about 27 kDa, corresponding to the monomeric mscFv 9O12. Two other minor peaks were also observed: one eluted at 11 mL (25%), and the other at 8 mL (13%). These minor peaks could correspond to the dimeric and multimeric forms of mscFv, as previously reported for other scFvs . After storage at 4 °C, the isolated dimeric and multimeric fractions were subjected to another gel filtration step. This resulted in a two-peak elution profile, one peak corresponding to the dimer, and the other to the monomer. The proportion of monomer increased when the dimer fraction was left for 3 days before being reapplied, demonstrating the instability of dimers and higher-order oligomers (data not shown). Monomeric scFv remained stable after prolonged storage at 4 °C. Affinity-purified scFv 9O12, but not the irrelevant scFv 9C2, was able to bind to GPVI in a dose-dependent manner in a direct ELISA, and competed with 9O12 (data not shown).
Functional properties of mscFv 9O12
Analysis of the scFv–GPVI interaction in real time using surface plasmon resonance (SPR) technology allowed us to determine the kinetic parameters of mscFv 9O12 using the BIAcore 2000 system and biaevaluation version 3.1 software (BIAcore, Uppsala, Sweden) (Fig. 2A). This gave the following kinetic parameters: kon = 6.5 × 104m−1·s−1, koff = 1.7 × 10−4·s1, and the dissociation constant KD = 2.6 nm. These parameters were similar to those calculated under the same conditions for the 9O12 proteolytic Fab fragment (KD = 2.3 nm) and parental IgG (KD = 4.0 nm). We investigated the ability of purified mscFv 9O12 to bind to immobilized GPVI after prolonged storage at 4 and 20 °C (for 3 days), and no significant decrease in antigen-binding ability was observed.
We also investigated whether the interaction of mscFv 9O12 with GPVI could inhibit the binding of GPVI to collagen immobilized on microtitration plates. GPVI preincubated with increasing amounts of antibody fragments was added to the wells. As shown in Fig. 2B, mscFv 9O12 inhibited GPVI (20 μg·mL−1) binding to collagen with an IC50 of approximately 1.17 μg·mL−1, 80% inhibition being reached at a concentration of 5–10 μg·mL−1 of mscFv 9O12. This inhibitory capacity was comparable to that observed for 9O12 Fab prepared after papain digestion of the parental IgG (2.1 μg·mL−1). Similar results were observed after incubation of GPVI (10 or 40 μg·mL−1) with the antibody fragments. In contrast, the irrelevant scFv 9C2 had no effect on the binding of GPVI to collagen.
Effects induced by mscFv 9O12 binding to GPVI
The binding of mscFv 9012 to native GPVI expressed at the platelet surface was further observed by flow cytometry, as indicated by the shift of the fluorescence peak to the right (Fig. 3A). Its ability to inhibit collagen-induced platelet aggregation was tested by light transmission aggregometry. The affinity-purified mscFv 9O12 (25 μg·mL−1) delayed the aggregation and reduced its extent from 65% to 25%, whereas the Fab was fully inhibitory (Fig. 3B). We further tested the monomeric form of mscFv 9O12 purified after size exclusion gel chromatography (Superdex 75 column) at the same concentration, and observed total inhibition of platelet aggregation, as observed with the Fab (not shown).
In addition, the effects of mscFv 9O12 on platelet adhesion and aggregation to collagen were investigated under arterial flow conditions, and compared with those of 9O12 Fab and an irrelevant scFv (Fig. 4). Once again, platelet aggregation induced by collagen was inhibited. In the presence of 9O12 fragments (scFv or Fab), only isolated platelets attached to the collagen fibers were observed, in agreement with previous results [20,23]. In contrast to control conditions, no large platelet aggregates were observed over a 5 min period.
As 9O12 Fab is known to inhibit thrombin generation at the surface of collagen-stimulated platelets, the effect of the purified mscFv 9O12 was tested using the thrombogram method (Fig. 5). mscFv 9O12 and 9O12 Fab reduced the thrombin peak to similar extents, and increased the lag preceding thrombin generation, indicating that mscFv 9O12 is as efficient as 9O12 Fab in inhibiting collagen-induced platelet procoagulant activity.
Humanization of mscFv 9O12 and functional evaluation
Murine antibodies would trigger an immune reaction if injected into human beings, and so humanization is required before any clinical investigation can be undertaken. To do this, we first constructed a 3D structural model of mscFv 9O12 in silico after identifying the crystal structures with sequences very similar to the 9O12 variable domains. All of these sequences were of murine origin. The top four scoring structures of murine origin were used for modeling. For the VH gene, we used antibodies designated 1PLG, 1MNU, 1A5F and 1IGI in the Protein Data Bank, which have 66–78% sequence identity (79–85% similarity) with 9O12. For the VL gene, we used antibodies 1PLG, 1IGI, 1MNU, and 1AXT, which have 87–90% sequence identity (94–95% similarity). The 3D structures of all these sequences were solved with a resolution higher than 2.8 Å. Twenty models were generated for each domain, using modeler 3.0 software, and the best one was selected on the basis of the rmsd value (0.13 Å for VH and 0.703 Å for VL) and detailed inspection. The model is shown in Fig. 6A.
We then proceeded to the humanization of 9O12 variable domains. To do this, fasta searches were performed to independently align VH and VL amino acid sequences against a repertoire of human antibody sequences registered in the Protein Data Bank. Among the human variable domains that matched 9O12, we first selected a VH domain and a VL domain from the same antibody molecule in order to preserve the interdomain contacts that occur in a natural antibody. The human antibody 1VGE was selected because it had the best identity score with 9O12 when the entire variable domain sequences were spanned, and was found to exhibit 62% and 55% identity with the VH domain and VL domain, respectively. When calculated over framework region (FR) sequences alone, the identity was even slightly better, at 69.5% and 65.4%, respectively. In addition, the crystallographic structure of 1VGE was solved at high resolution (2 Å and R = 0.18). We therefore decided to graft 9O12 CDRs onto the 1VGE template in silico. A gene encoding this construct was chemically synthesized, and inserted into pSWI exactly as had been done for mscFv 9O12. TOPPI cells transformed with this vector were induced to express the recombinant protein. However, the recombinant protein was never detected in the periplasm of induced bacteria, and so some refinements of the construct were called for. First, we observed that 9O12 V-kappa CDR1 is five residues longer than that of the template (1VGE), and that 9O12 and 1VGE V-kappa FR1 and FR2 have low identity scores (48% and 73%, respectively) (Fig. 6C). Extra fasta searches were then performed using 9O12 V-kappa FR1 and FR2. An excellent match was found with V-kappa FR1 and FR2 from human antibody 1X9Q (95.6% and 86.6% identity scores, respectively, and 100% similarity in both cases). In addition, V-kappa CDR1 of the selected antibody 1X9Q was similar in length to that of 9O12. We therefore decided to preserve the original 9O12 V-kappa FR1 and FR2 in the novel humanized scFv construction. Other refinements were carried out on the basis of close inspection of the model, and the final construct is shown in Fig. 6B. All of the humanized 9O12 frameworks exhibit 100% similarity with human frameworks, apart from the IGHV and V-kappa FR3 (90.62% and 93.75%, respectively) (Table 1). The 11 N-terminal residues from the murine IGHV FR3 were preserved in the final construct, because they are clearly located close to the flat part of the pocket in which the antigen is expected, and so could interact with it. Nevertheless, IGHV FR3 exhibits 25/32 residue identity with 1VGE. Only three residues of this framework (Ala71, Lys73, and Arg76; Kabbat numbering) had no similarity with 1VGE. The 9O12 V-kappa FR3 was substituted for its 1VGE counterpart, with the exception of two residues (L59P and D60S), essentially because Leu is not frequently encountered at this position, and Asp is an acidic residue.
Table 1. Identity and similarity scores of the 9O12 humanized variable domain frameworks, with human antibody frameworks used as template; x is the number of residues in the humanized FR that are identical to residues from the human FR; y is the total number of residues in the FR.
The gene encoding the scFv in which humanized 9O12 variable domains are fused together via the short flexible linker (G4S)3 was synthesized and cloned into the pSW1 vector. The final humanized scFv 9O12 protein (hscFv 9O12) was produced in the periplasm of recombinant ToppI E. coli cells and purified to homogeneity by affinity chromatography using GPVI–Sepharose bead columns. A single band with the size expected (28 kDa) was observed after SDS/PAGE. However, the production yield of hscFv9O12 was very low. We observed a slightly better level of expression when using BL21DE3 E. coli transformed with pET-22–hscFv 9O12 (60 μg·L−1 of culture), and we selected this expression system to produce hscFv 9O12 for further characterization (Fig. 7A). The purified hscFv 9O12 conserved high affinity for its target, as demonstrated by SPR analysis against immobilized GPVI (kon = 5.8 × 104m−1·s−1, koff = 1.86 × 10−4 s−1, and dissociation constant KD = 3.2 nm) (Fig. 7B). It was also able to bind to freshly prepared human platelets in flow cytometry, and the shift to the right of the fluorescence peak was similar to that of cells labeled with mscFv 9O12 under similar experimental conditions (Fig. 7C). Finally, nearly total inhibition of hscFv 9O12 binding was observed when platelets were premixed with an excess of 9O12 Fab. In addition, hscFv 9O12 binding to platelets inhibited platelet activation induced by convulxin which is a specific GPVI agonist . Indeed, P-selectin exposure was not observed at the surface of platelets preincubated with hscFv 9O12 and then activated by convulxin (Fig. 8A). In addition, we observed that hscFv 9O12 inhibited the aggregation of platelets induced by collagen but not by thrombin or the thrombin receptor agonist peptide (TRAP), which demonstrates that hscFv 9O12 inhibition is GPVI-dependent (Fig. 8B).
Platelets play a crucial role in arterial thrombosis and represent a major therapeutic target. All the drugs currently available act on late phases of thrombus formation, and their use is often associated with major drawbacks, such as prolongation of the bleeding time and/or induction of thrombocytopenia. Acting at an earlier stage of the platelet aggregation process could offer several advantages. GPVI and GPIa–IIa are the main platelet receptors, interacting directly with the collagen exposed by the subendothelial matrix as a result of vascular injury, but GPVI is the only one specifically expressed at the surface of platelets. Early GPVI interaction with collagen is a major event leading to platelet activation, the release of secondary agonists, and thrombus formation. Thus, inhibition of GPVI–collagen interaction could have potent antithrombotic effects. This has been demonstrated both in vitro and under physiological conditions in vivo. Deficiency in GPVI expression does not lead to impaired hemostasis in mice or humans [6,10]. Furthermore, anti-GPVI molecules inhibit thrombus growth without producing any significant side effects [8,10].
In this context, the need for better antithrombotic drugs, and the emergence of numerous antibody-derived molecules approved for the treatment of a wide range of disorders, have stimulated the search for potent antithrombotic antibodies. This is exemplified by the chimeric mouse–human Fab abciximab (ReoproR), which blocks the platelet GPIIb–IIIa receptor, and is now used for the treatment of patients with acute coronary syndrome undergoing percutaneous coronary surgery [25,26].
Few antibody molecules directed against GPVI have been prepared, because GPVI cDNA has only recently been cloned and expressed as a recombinant soluble protein [5,27]. Some anti-GPVI scFvs have been selected after panning phage libraries expressing nonimmune human repertoires [13–15]. However, this approach has not yet been demonstrated to be fully effective. Indeed, although some of the anti-GPVI scFvs isolated do lead to dose-dependent inhibition of the GPVI–collagen interaction in vitro, they have a weak affinity for GPVI, making them unsuitable for clinical investigations. Such difficulties may be related to technical problems, including difficulties in constructing large libraries of scFvs, maintaining the repertoire over time, and slowing its inevitable drift .
All of the high-affinity antibodies against GPVI isolated so far have been prepared using the more conventional hybridoma technology after immunization of Balb/C mice with 3T3 fibroblasts expressing human GPVI or with the cDNA encoding the human GPVI protein, as is the case for 9O12, or after inoculation of GPVI-knockout mice with transfected Chinese hamster ovary cells expressing human GPVI and FcRγ, as has recently been reported [17,18,20,29]. Some of these antibodies are devoid of blocking activity, such as HY101, 6B12, and 3J24.2 [29–31]. Others have good potential in terms of their biological and pharmacological properties, displaying direct blocking activity against the GPVI–collagen interaction when tested as monovalent Fab fragments. In addition, the ex vivo antithrombotic effects of anti-GPVI Fabs obtained by papainolysis of murine IgGs OM4 and 9O12 have been observed in nonhuman primates without the induction of platelet GPVI depletion [18,32]. For all of these reasons, 9O12 is an excellent template to use when designing antithrombotic molecules with potential human clinical applications.
Murine antibodies are highly immunogenic when injected into humans, and thus they have to be chimerized or humanized for therapeutic applications . Chimerization is achieved by transferring variable domains to human constant antibody domains. The chimeric Fab abciximab, which binds to the platelet fibrinogen receptor GPIIb–IIIa, inhibits thrombus growth, but it still induces adverse immune responses against mouse epitopes in small groups of patients . A humanized antibody, ‘eculizumab’, has recently been approved by the US Food and Drug Administration for the chronic treatment of paroxysmal nocturnal hemoglobinuria. It is nonimmunogenic, safe, and well tolerated . Several possible methods of humanizing antibody variable domains have been suggested [36–38]. None of these methods is simple, and all often result in impaired specificity and/or affinity [39–42].
In view of the functional properties of the murine 9O12 Fab fragment, we designed and evaluated the activity of derived scFvs that can be viewed as possible building blocks for future drug development. First, murine scFv 9O12 was engineered with the intention of determining the 9O12 variable domain sequences and checking their functionality when produced as a recombinant molecule in a heterologous expression system. Affinity-purified scFv preserved high functional affinity for GPVI, which allowed it to block collagen-induced platelet aggregation, and inhibit thrombus formation under flow conditions as well as preventing thrombin generation. To reduce the immunogenicity of mscFv, we then proceeded to humanize it by a procedure essentially based on CDR grafting combined with refinements based on in silico modeling. The final product reported here exhibits 100% similarity with human antibody frameworks, with the exception of VH FR3 (90.62%) and VL FR3 (93.75%), and its framework sequences differ by 25 residues from that of mscFv 9O12. The strategy consisted of grafting murine CDRs onto the frameworks of human antibody 1VGE in order to preserve interdomain contacts. This strategy was effective, but required further refinement. Indeed, during this first attempt, the recombinant scFv resulting from the grafting of 9O12 CDRs onto 1VGE frameworks was not produced efficiently. We postulated unforeseen structural incompatibilities between the original murine CDRs and the human acceptor frameworks that could have led to misfolding of the variable domains. To circumvent these difficulties, some minor refinements were made. First, we observed that 9O12 V-kappa CDR1 is particularly long and has five more residues than 1VGE, suggesting that 1VGE V-kappa FR1 and FR2 are not suitable for the correct folding of CDR1. Back-mutation to 9O12 wild-type V-kappa FR1 and FR2 was therefore required, and this was encouraged by the observation that the sequences of these murine frameworks fit well with another human antibody framework (1X9Q). V-kappa CDR1 of antibody 1X9Q is exactly the same size as that of 9O12 (Fig. 6). We also retained in the final construct a very limited number of residues that could influence the ability of CDR loops to adopt their conformation.
Two critical areas were preserved. The first one was the dipeptide Leu-Asp at position 59–60 in the V-kappa domain. Leu59 (Pro in the human template) was considered to be potentially significant, as it is in the close vicinity of the residues of V-kappa CDR2. Although Leu and Pro are both hydrophobic, Pro has a cyclical side chain and is known to have specific effects on the protein backbone structure . In addition, we noticed that Leu occurs much less often than Pro at this position (2%), and this may be indicative of a specific role . The other unmutated murine residues with no similarities to the human template (1VGE) were located in IGHV FR3 (Ala71, Lys73, and Arg76; Kabbat numbering). In silico observations and previous analysis have shown that Ala71 has an important role in the conformation of IGHV CDR2 . Finally, only five murine residues in V-kappa and 10 in IGHV were maintained in the human frameworks selected for humanization. Other humanized scFvs reported in the literature have almost always required the insertion of numerous murine residues into the reshaped molecule in order to preserve strong binding activity and specificity . fasta searches of the final humanized IGHV and V-kappa sequences (with the exclusion of the CDRs) against the UniProt data bank showed that the five best-fitting sequences were all derived from human antibodies, whereas the same search performed for murine 9O12 variable domains led exclusively to murine antibody sequences.
The main parameters usually affected by humanization were well preserved in our final product. Affinity-purified hscFv 9O12 was fully functional, with high affinity for GPVI, a major point for biological applications. Fluorescence-activated cell sorting analysis also indicated that hscFv 9O12 recognizes the same epitope on human platelets as mouse 9O12 Fab, because its binding was specifically blocked in the presence of a molar excess of 9O12 Fab. However, despite the use of codons optimized for prokaryotic expression in the synthetic cDNA encoding hscFv 9O12, the production yield remained low, and other expression systems will have to be tested in the future [47,48]. For this reason, the ability of hscFv to inhibit aggregation in flow conditions was not investigated here. However, we clearly demonstrate that binding of hscFv 9O12 inhibits GPVI-dependent platelet activation and aggregation.
In conclusion, this study provides the first experimental evidence that murine anti-human GPVI platelets can be humanized without deleterious effects, making hscFv 9O12 a powerful building block for the generation and evaluation of new compounds with potentially therapeutic antithrombotic properties.
Hybridoma cell line 9O12 secreting a monoclonal IgG1,k directed against the GPVI of human platelets, and IgG and Fab fragment preparation and purification, have been reported previously . The scFv 9C2 directed against a scorpion toxin, irrelevant to GPVI, was prepared as in . The antibody against flag (9E10) was used either free or conjugated to horseradish peroxidase (Sigma-Aldrich, Saint Quentin Fallavier, France) or to fluorescein isothiocyanate (FITC) (Invitrogen, Cergy Pontoise, France). FITC-coupled goat anti-mouse IgGs were from Sigma-Aldrich.
The recombinant soluble human GPVI protein, consisting of two extracellular domains of the receptor, coupled to the Fc fragment of human IgG1 was produced and purified as in . GPVI was coupled to cyanogen bromide-activated Sepharose according to the manufacturer’s instructions (Amersham-Pharmacia, Les Ulis, France). The gel was stored at 4 °C in NaCl/Pi containing sodium azide (1%).
Blood was collected from healthy volunteers. Washed human platelets were obtained according to a previously described procedure .
All chemicals were of standard grade from Sigma-Aldrich or equivalent.
Construction of the single chain antibody genes
mRNA was isolated from freshly subcloned hybridoma 9O12. cDNAs encoding the antibody variable domains (V-kappa and IGHV) were cloned after RT-PCR, essentially as previously reported [21,22]. Murine scFv 9O12 was created by PCR splicing with overlap extensions using oligonucleotides that encode the (G4S)3 peptide linker between the C-terminus of IGHV and the N-terminus of V-kappa. First, IGHV and V-kappa genes were modified by PCR amplification with primers VHRev and VHlinkFor or VLlinkRev and VLFor, respectively. VHRev (5′-CAG GTG CAG CTG CAG GAG TCA GG-3′) encoded the N-terminal sequence of IGHV containing a PstI site, and VHlinkFor (5′-ACC ACC GGA TCC GCC TCC GCC TGA GGA GAC GGT GAC CGT-3′) encoded the C-terminus of IGHV and part of the linker. VLlinkRev (5′-GGA GGC GGA TCC GGT GGT GGC GGA TCT GGA GGT GGC GGA AGC GAT GTT TTG ATG ACC CAA ACT CCA CT-3′) and VLFor (5′-GAC CCT CGA GCG TTT GAT CTC CAG CTT GGT-3′), which contains a XhoI site, were used to amplify and modify the V-kappa domain. Both genes were assembled by ‘splicing by overlap extension’ with primers VHRev and VLFor. The gene fragment of the appropriate size was purified, cleaved with PstI and XhoI, and cloned into the expression vector pSWI restricted in the same manner before being sequenced. This made it possible to clone the scFv gene in-frame with the pelB leader sequence at its 5′-end and, downstream, a sequence encoding the c-Myc tag. The constructed vector pSW–mscFv9O12 was cloned into the ToppI E. coli strain (Stratagene, La Jolla, USA).
Computational analysis and synthetic gene design
Frameworks and the hypervariable loops (CDRs) of antibody variable domains were identified using the Kabbat nomenclature . An in silico 3D model of 9O12 Fv was constructed by homology modeling based on V-kappa and IGHV domains with maximum sequence identity and a known tertiary structure. First, the protein structure sequence Protein Data Bank was searched for antibody sequence similarities with each individual 9O12 variable domain, using the fasta 3 program at the European Bioinformatics Institute (EMBL-EBI, Cambridge, UK). Then, modeler 3.0 software (Accelerys, San Diego, CA, USA) was used to generate up to 20 models for each variable domain, the best one being selected on the basis of the rmsd value.
To design a humanized scFv (hscFv), the 9O12 variable domain sequences were independently subjected to a fasta search against the Protein Data Bank, and the closest human antibody variable domains were selected. The same search was also performed after excluding the CDR regions. The scaffolds of variable domains belonging to the same antibody molecule were chosen in order to minimize the risk of lowering the stability of the interaction between variable domains in the recombinant scFvs while attempting to preserve the scaffold required for the integrity of the antigen-binding site. In the first step, the human antibody 1VGE variable domains were selected as templates, and the murine 9O12 CDRs were grafted onto them in silico. The framework sequences were inspected to see whether any buried residues had been conserved. The packing of the grafted loops was also evaluated by visual inspection, and FR refinements were performed by in silico substitution.
The changes in the amino acids required for the humanization were obtained by de novo DNA synthesis. Optimization of the DNA design was performed using the codon usage table for expression in E. coli cells . Restriction sites were also inserted at the extremities of the CDRs to make it possible to carry out the cDNA sequence adjustments that would be required to optimize the structural or functional characteristics of the recombinant protein. The synthetic gene encoding hscFv 9O12 was cloned into the expression vector pSW1 restricted with PstI and XhoI, leading to a vector designated pSW–hscFv 9O12, which allows periplasmic expression of hscFv 9O12 fused to the c-Myc tag. The gene encoding hscFv 9O12 fused to the c-Myc tag was also cloned into the pET-22b(+) vector (Merck Chemicals Ltd., Nottingham, UK), which carries a T7 promoter. To do this, the sequence encoding hscFv 9O12 fused to the c-Myc tag was first reamplified from pSW–hscFv 9O12 by PCR using primers VHpEtRev (5′-TG GCC ATG GCC CAG GTG CAG CTG CAG G-3′) and 9O12pEtFor (5′-TG GTG CGG CCG CTT ATT AAT TCA GAT CCT CTT CTG A-3′). The amplified cDNA was then digested with NcoI and NotI, leading to a 820 bp sequence that was cloned in-frame with the pelB leader sequence into pET-22b(+) restricted in the same manner. The constructed vector, designated pET-22–hscFv 9O12, was cloned into the BL21DE3 E. coli strain (Merck Chemicals Ltd.).
Production and purification of recombinant antibody fragments
For expression of the recombinant scFvs, bacteria containing the desired plasmids were grown in 500 mL of 2× TY medium (Difco, Le Pont de Claix, France) containing ampicillin (100 μg·mL−1) at 37 °C under rotative agitation (125 r.p.m.), until A600 nm reached 0.6 (BL21DE3 E. coli) or 1.5 (ToppI E. coli). Then, 0.8 mm isopropyl-thio-β-d-galactoside was added to the medium, and incubation was continued for 16 h at 16 °C under rotative agitation (75 r.p.m.) to induce scFv production. Bacteria were then collected by centrifugation (3600 g, 20 min, 4 °C). Periplasmic extracts containing scFv were prepared by resuspending the pellet in 10 mL of ice-cold TES buffer (0.2 m Tris/HCl, pH 8.0, containing 0.5 mm EDTA and 0.5 m sucrose), and incubating for 30 min. Cells were subjected to osmotic shock by adding TES buffer diluted 1 : 4 for 30 min on ice, and then centrifuging at 15 000 g for 30 min at 4 °C to remove insoluble material. Deoxyribonuclease A (50 U) and aprotinin (2 μg·mL−) were added to the supernatant before extensive dialysis against NaCl/Pi at 4 °C.
To purify scFv, the periplasmic extract (30 mL) was incubated with 500 μL of GPVI coupled to Sepharose beads for 12 h at 4 °C and for 4 h at room temperature. The mixture was loaded onto a microcolumn. After washing with NaCl/Pi at pH 7.4, bound proteins were eluted with 0.1 m glycine-HCl (pH 3.0) in 0.4 mL fractions, and immediately neutralized with 5 μL of 3 m Tris on ice. Fractions with A280 nm higher than 0.2 were pooled and extensively dialyzed against NaCl/Pi.
The purity was checked by SDS/PAGE using a 15% gel followed by staining with Coomassie brilliant blue, or by western blotting and immunostaining with horseradish peroxidase-coupled antibody against c-Myc, essentially as in . The integrity of the purified recombinant protein was also investigated by MALDI-TOF MS on a 4700 Proteomics Analyzer MALDI-time of flight (TOF)/TOF apparatus (Applied Biosystems, Foster City, CA, USA).
Finally, the affinity-purified scFv (200 μl, 100 μg·mL−) was analyzed by gel filtration using a Superdex 75 column (Amersham Bioscience, Les Ulis, France) calibrated using standards from Boehringer Mannheim (Meylan, France). Proteins were eluted with NaCl/Pi at a flow rate of 0.5 mL·min−1, and detected with a UV recorder at 280 nm.
The concentration of the purified scFvs was evaluated after measuring their absorbance at 280 nm, and using the Swiss Institute of Bioinformatics software (protparam tool) to determine the theoretical molecular mass of the recombinant scFvs and their extinction coefficient . Affinity-purified hscFv 9O12 was aliquoted and stored at −20 °C in NaCl/Pi containing 0.1% BSA until further use.
Immunochemical characterization of the scFv fragments
Microtitration plates were coated with GPVI in NaCl/Pi (10 μg·mL−1, 100 μL per well) overnight at 4 °C. Nonspecific binding sites were saturated with 100 μL of 1% BSA in NaCl/Pi for 90 min. The plates were then incubated with increasing concentrations of the scFv preparation (0–20 μg·mL−1; 100 μL) for 90 min. They were incubated for an additional 90 min with peroxidase-coupled antibody against c-Myc (100 μL, 1 : 750 in NaCl/Pi). All incubations were carried out at room temperature. Finally, 100 μL of the substrate solution (orthophenylene diamine; Sigma-Aldrich) was added to each well for 5 min, and the absorbance was read at 492 nm. Two controls were performed: the first one used the irrelevant scFv 9C2 instead of scFv 9O12, and for the second, coating with GPVI was omitted. Five washes with NaCl/Pi containing 0.05% Tween and 0.1 mg·mL−1 BSA were performed between each of the intermediate steps. In competitive assays, scFv 9O12 (100 μg·mL−1) was mixed with increasing concentrations of 9O12 (0–100 μg·mL−1), before being delivered into GPVI-coated microtitration wells. Bound scFv was detected as described above.
The BIAcore 2000 instrument and all the reagents for analysis were obtained from BIAcore. GPVI was immobilized (approximatively 600 RU) on a carboxymethyldextran CM5 sensor chip activated with a 1 :1 mix of N-hydroxysuccinimide (50 mm) and N-ethyl-N′-(dimethylaminopropyl)-carbo-di-imide (200 mm) by a 7 min pulse. Affinity-purified antibody fragments were then passed over the immobilized GPVI in HBS-EP buffer [0.01 m Hepes (pH 7.4), 0.15 m NaCl, 0.005% polysorbate 20 (v/v)] at a flow rate of 20 μL·min−1 at 25 °C. Glycine-HCl (10 mm, pH 2.5) was injected for 30 s at 20 μL·min−1 to regenerate the sensor chip between successive samples. Kinetic constants (kon, koff) were deduced from the analysis of association and dissociation rates at four different antibody fragment concentrations, ranging from 5 to 40 μg·mL−1.The dissociation constant KD was calculated from KD = koff/kon. Sensorgrams were analyzed using biaevaluation version 3.1 software. All experiments were carried out in quadruplicate at the Institute Jacques Monod platform (Paris, France).
Washed human platelets (2 × 107 mL−1) from several healthy volunteers were incubated for 30 min at room temperature with 10–40 μg·mL−1 purified scFv, and then incubated again for 30 min at room temperature with 5 μL of FITC-coupled anti-c-Myc IgG (dilution 1 : 60). Cell fluorescence was measured using a flow cytometer (Epics XL, Beckman Coulter, Villepinte, France). Background was determined by using the irrelevant scFv 9C2 instead of the scFv 9O12 variants. All incubations were carried out in the dark. When 9O12 Fab (40 μg·mL−1) binding to platelets was investigated, FITC-conjugated goat anti-(mouse IgG) (Sigma-Aldrich) (1 : 100) was used instead of the FITC-coupled anti-c-Myc IgG.
scFv binding inhibition
Cells were incubated with blocking Fab 9O12 (10 μg·mL−1) for 10 min. They were then mixed with purified hscFv 9O12 (40 μg·mL−1), and incubated for 30 min. Finally, 5 μL of FITC-coupled anti-c-Myc IgG (diluted 1 : 60) was added to the cells for a further 30 min before analysis of the cell suspension by flow cytometry.
Inhibition of platelet activation
Platelets were incubated for 30 min. with scFv (10–40 μg·mL−1) or NaCl/Pi. Then, platelets were activated with convulxin (0.3 nm) for 15 min at 20 °C. Five microliters of an anti-P-selectin IgG conjugated to FITC (Beckman Coulter, Villepinte, France) was added to the cells for 30 min before analysis of the cell suspension by flow cytometry. All experiments were carried out at least in triplicate.
Ability of the antibody fragments to block GPVI binding to collagen
Wells of a microtitration plate (Immulon 2; Dynex, VWF, France) were coated overnight with 100 μL of collagen type I (equine tendon; Horm, Nycomed, Munich) (20 μg·mL−1) and blocked with BSA (0.2% in NaCl/Pi) for 2 h. Then, 100 μL of GPVI (10, 20 or 40 μg·mL−1) that had been preincubated for 30 min with increasing amounts of antibody fragments (0–20 μg·mL−1) was added to each well. After incubation for 2 h, the bound GPVI was detected using a peroxidase-coupled anti-human Fc (Jackson Immuno-Research Labs Inc., West Grove, PA, USA) and orthophenylene dimine. All incubations were performed at room temperature, and five washes with 300 μL of NaCl/Pi containing 0.1% Tween-20 and 1% BSA were carried out between each step. All assays were conducted in triplicate. The percentage of residual GPVI binding to collagen was determined using mean values.
Platelet aggregation assays
Washed human platelets (3 × 108 mL−1) were preincubated for 5 min at 37 °C with antibody fragments in NaCl/Pi (25 μg·mL−1), without stirring. Platelet aggregation was then initiated by adding type I collagen to a final concentration of 1 μg·mL−1, or thrombin (1 nm) or the thrombin receptor agonist peptide TRAP (10 μm) . Platelet aggregation induced changes in light transmission that were continuously recorded (Chronolog Aggregometer Chrono Log Corp., Harveston, PA, USA).
Platelet aggregation under flow conditions
Platelet adhesion to collagen under flow conditions was measured essentially as described previously . Glass coverslips were coated with fibrillar type I collagen (50 μg·mL−1). Blood from healthy volunteers was collected on 40 μm PPACK, and labeled with DIOC-6 (1 μm). Blood aliquots were incubated for 15 min at room temperature with buffer or purified antibody fragment (9O12 Fab, mscFv 9O12, scFv 9C2) at a final concentration of 50 μg·mL−1. The mixture was then perfused over the collagen-coated coverslips inserted in a flow chamber at 1500 s−1 for 5 min. Transmission and fluorescent images were recorded in real time using a fluorescence microscope. Fluorescent images were obtained from at least 10 different collagen-containing microscopic fields, which were arbitrarily chosen at the end of perfusion. The area coverage of fluorescent images was analyzed off-line using histolab software (Microvision, Evry, France). Assays were performed using blood from two healthy volunteers and two distinct preparations of affinity-purified scFv.
Thrombin generation was continuously measured in platelet-rich plasma (PRP) using the thrombogram method as previously described . Briefly, citrated PRP (1.5 × 108 platelets mL−1) was incubated with the antibody fragments (50 μg·mL−1) for 10 min at 37 °C before addition of the collagen (5 μg·mL−1). Ten minutes later, thrombin generation was initiated by transferring the samples into the wells of a microtitration plate containing tissue factor (0.5 pm). After 5 min at 37 °C, the reaction was initiated by addition of buffer containing CaCl2 (16.6 mm) and the fluorescent thrombin substrate Z-GGR-AMC (Stago, Asnières, France). Fluorescence accumulation of the cleaved substrate was continuously measured at excitation and emission wavelengths of 390 and 460 nm, respectively. First derivative curves of fluorescence accumulation were converted into thrombin concentration curves using a thrombin calibrator . The peak height is an indicator of the maximum rate of thrombin formation, and is sensitive to platelet activation.
We are indebted to J. M. Camadro for stimulating discussions. We also acknowledge the invaluable technical help provided by S. Loyau. J. Muzard was a research fellow of Stago (Asnières, France) and the Fondation pour la Recherche Médicale (FRM). This work was supported by grant no. 2007001960 from the Fondation de France and grant no. 07-EMPB-002-01 from the Agence Nationale de la Recherche (ANR).